| Literature DB >> 29455176 |
Hiroyuki Mori1, Kei Ebisawa1, Mitsushige Nishimura2, Kenji Kanazawa3.
Abstract
Extranodal natural killer (NK)/T cell lymphoma, nasal type is a condition that has poor prognosis. Accurate diagnosis of lymphoma is made by pathological findings. We report a case of extranodal NK/T cell lymphoma, nasal type affecting the lung and liver and which was difficult to diagnose because of negative biopsy results from multiple sites. A 39-year-old man who had dry cough and fever for 1 month was referred to our hospital. He had pancytopenia and elevated serum levels of lactate dehydrogenase and soluble interleukin-2 receptor. Hepatosplenomegaly and multiple lung nodules were found on imaging study. Specimens of bronchoscopic lung, percutaneous liver, bone marrow and random skin biopsies were all negative. Open lung biopsy was not definitive. Unfortunately, disease progression was rapid and fatal before results of pleural fluid cytology and a second liver biopsy showed extranodal NK/T cell lymphoma, nasal type. This report focused on diagnostic planning for rapidly progressive extranodal NK/T-cell lymphoma, nasal type. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.Entities:
Keywords: malignant and benign haematology; medical management
Mesh:
Year: 2018 PMID: 29455176 PMCID: PMC5836627 DOI: 10.1136/bcr-2017-221019
Source DB: PubMed Journal: BMJ Case Rep ISSN: 1757-790X
Figure 1Chest X-ray showing multiple nodular lesions bilaterally.
Figure 2Chest CT imaging showing multiple nodular lesions bilaterally.
Figure 3Abdominal CT imaging showing hepatosplenomegaly.
Figure 4(A) Pleural effusion micropathology showing immature lymphocytes with irregular karyotype. (B) Liver micropathology showing immature lymphocytes with irregular karyotype.
Figure 5Immunohistochemical staining of pleural effusion showing positive for CD3, CD56 and Epstein-Barr encoding region (EBER), but negative for CD20.